Pectic polysaccharide isolated from Angelica gigas Nakai inhibits melanoma cell metastasis and growth by directly preventing cell adhesion and activating host immune functions

Cancer Letters

Volumn 243, Issue 2, 2006, Pages 264-273

  Han, Sang Bae ^a   Lee, Chang Woo ^a   Kang, Moo Rim ^a   Yoon, Yeo Dae ^a   Kang, Jong Soon ^a   Lee, Ki Hoon ^a   Yoon, Won Kee ^a   Lee, Kiho ^a   Park, Song Kyu ^a   Kim, Hwan Mook ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Adhesion; Angelica gigas Nakai; Invasion; Metastasis; Tumor growth

Indexed keywords

ANGELAN; DOXORUBICIN; POLYSACCHARIDE; UNCLASSIFIED DRUG;

ANGELICA GIGAS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CANCER INHIBITION; CELL ACTIVATION; CELL ADHESION; CELL SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXICITY; EXTRACELLULAR MATRIX; FEMALE; LUNG METASTASIS; MACROPHAGE; MEDICINAL PLANT; MELANOMA; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANGELICA; ANIMALS; B-LYMPHOCYTES; CELL ADHESION; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; INJECTIONS, INTRAPERITONEAL; MACROPHAGES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; PLANT PREPARATIONS; POLYSACCHARIDES; SURVIVAL RATE; T-LYMPHOCYTES;

ANGELICA GIGAS;

EID: 33749426610     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.11.040     Document Type: Article

References (36)

1. Mushiake H., Tsunoda T., Nukatsuka M., Shimao K., Fukushima M., and Tahara H. Dendritic cells might be one of key factors for eliciting antitumor effect by chemoimmunotherapy in vivo. Cancer Immunol. Immunother. 54 (2005) 120-128
2. Salgaller M.L., and Lodge P.A. Use of cellular and cytokine adjuvants in the immunotherapy of cancer. J. Surg. Oncol. 68 (1998) 122-138
3. Kanazawa M., Yoshihara K., Abe H., Iwadate M., Watanabe K., Suzuki S., et al. Effects of PSK on T and dendritic cells differentiation in gastric or colorectal cancer patients. Anticancer Res. 25 (2005) 443-449
4. Okamoto M., Ohe G., Furuichi S., Nishikawa H., Oshikawa T., Tano T., et al. Enhancement of anti-tumor immunity by lipoteichoic acid-related molecule isolated from OK-432, a streptococcal agent, in athymic nude mice bearing human salivary adenocarcinoma: role of natural killer cells. Anticancer Res. 22 (2002) 3229-3239
5. Wustrow T.P., and Mahnke C.G. Causes of immunosuppression in squamous cell carcinoma of the head and neck. Anticancer Res. 16 (1996) 2433-2468
6. Zaidman B.Z., Yassin M., Mahajna J., and Wasser S.P. Medicinal mushroom modulators of molecular targets as cancer therapeutics. Appl. Microbiol. Biotechnol. 67 (2005) 453-468
7. Cao W., Chi W.H., Wang J., Tang J.J., and Lu Y.J. TNF-alpha promotes doxorubicin-induced cell apoptosis and anti-cancer effect through downregulation of p21 in p53-deficient tumor cells. Biochem. Biophys. Res. Commun. 330 (2005) 1034-1040
8. Guadagno T.M., and Newport J.W. Cdk2 kinase is required for entry into mitosis as a positive regulator of Cdc2-cyclin B kinase activity. Cell 84 (1996) 73-82
9. Rosenblatt J., Gu Y., and Morgan D.O. Human cyclin-dependent kinase 2 is activated during the S and G2 phases of the cell cycle and associates with cyclin A. Proc. Natl Acad. Sci. USA 89 (1992) 2824-2828
10. Han S.B., Kim Y.H., Lee C.W., Park S.M., Lee H.Y., Ahn K.S., et al. Characteristic immunostimulation by angelan isolated from Angelica gigas Nakai. Immunopharmacology 40 (1998) 39-48
11. Jeon Y.J., Han S.B., Ahn K.S., and Kim H.M. Activation of NF-kappaB/Rel in angelan-stimulated macrophages. Immunopharmacology 43 (1999) 1-9
12. Jeon Y.J., Han S.B., Ahn K.S., and Kim H.M. Differential activation of murine macrophages by angelan and LPS. Immunopharmacology 49 (2000) 275-284
13. Jeon Y.J., Han S.B., Lee S.H., Kim H.C., Ahn K.S., and Kim H.M. Activation of mitogen-activated protein kinase pathways by angelan in murine macrophages. Int. Immunopharmacol. 1 (2001) 237-245
14. Jeon Y.J., and Kim H.M. Experimental evidences and signal transduction pathways involved in the activation of NF-kappa B/Rel by angelan in murine macrophages. Int. Immunopharmacol. 1 (2001) 1331-1339
15. Han S.B., Lee C.W., Jeon Y.J., Hong N.D., Yoo I.D., Yang K.H., and Kim H.M. The inhibitory effect of polysaccharides isolated from Phellinus linteus on tumor growth and metastasis. Immunopharmacology 41 (1999) 157-164
16. Hibino S., Shibuya M., Engbring J.A., Mochizuki M., Nomizu M., and Kleinman H.K. Identification of an active site on the laminin alpha5 chain globular domain that binds to CD44 and inhibits malignancy. Cancer Res. 64 (2004) 4810-4816
17. Rothhammer T., Poser I., Soncin F., Bataille F., Moser M., and Bosserhoff A.K. Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res. 65 (2005) 448-456
18. Han S.B., Moratz C., Huang N.N., Kelsall B., Cho H., Shi C.S., et al. Rgs1 and Gnai2 regulate the entrance of B lymphocytes into lymph nodes and B cell motility within lymph node follicles. Immunity 22 (2005) 343-354
19. Han S.B., Park S.K., Ahn H.J., Yoon Y.D., Kim Y.H., Lee J.J., et al. Characterization of B cell membrane receptors of polysaccharide isolated from the root of Acanthopanax koreanum. Int. Immunopharmacol. 3 (2003) 683-691
20. Han S.B., Yoon Y.D., Ahn H.J., Lee H.S., Lee C.W., Yoon W.K., et al. Toll-like receptor-mediated activation of B cells and macrophages by polysaccharide isolated from cell culture of Acanthopanax senticosus. Int. Immunopharmacol. 3 (2003) 1301-1312
21. Borchers A.T., Keen C.L., and Gershwin M.E. Mushrooms, tumors, and immunity: an update. Exp. Biol. Med. (Maywood) 229 (2004) 393-406
22. Borchers A.T., Stern J.S., Hackman R.M., Keen C.L., and Gershwin M.E. Mushrooms, tumors, and immunity. Proc. Soc. Exp. Biol. Med. 221 (1999) 281-293
23. Brown G.D., and Gordon S. Fungal beta-glucans and mammalian immunity. Immunity 19 (2003) 311-315
24. Hong F., Hansen R.D., Yan J., Allendorf D.J., Baran J.T., Ostroff G.R., and Ross G.D. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res. 63 (2003) 9023-9031
25. Hong F., Yan J., Baran J.T., Allendorf D.J., Hansen R.D., Ostroff G.R., et al. Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J. Immunol. 173 (2004) 797-806
26. Furukawa T., Kubota T., Watanabe M., Kuo T.H., Kase S., Saikawa Y., et al. Immunochemotherapy prevents human colon cancer metastasis after orthotopic onplantation of histologically-intact tumor tissue in nude mice. Anticancer Res. 13 (1993) 287-291
27. Furukawa T., Kubota T., Watanabe M., Kuo T.H., Kitajima M., and Hoffman R.M. Differential chemosensitivity of local and metastatic human gastric cancer after orthotopic transplantation of histologically intact tumor tissue in nude mice. Int. J. Cancer 54 (1993) 397-401
28. Carter S.K. Adriamycin-a review. J. Natl Cancer Inst. 55 (1975) 1265-1274
29. Anand A., and Anand A. Paclitaxel in doxorubicin-resistant metastatic breast cancer patients. J. Natl Cancer Inst. 87 (1995) 1642
30. Ohishi K., Morinaga Y., Ohsumi K., Nakagawa R., Suga Y., Tsuji T., et al. Potentiation of antitumor and antimetastatic activities of adriamycin by a novel N-alkylated dihydropyridine, AC394, and its enantiomers in colon cancer-bearing mice. Cancer Chemother. Pharmacol. 38 (1996) 446-452
31. Benbow U., Maitra R., Hamilton J.W., and Brinckerhoff C.E. Selective inhibition of collagenase-1, gelatinase A, and gelatinase B by chemotherapeutic agents. Ann. NY Acad. Sci. 878 (1999) 662-664
32. Benbow U., Maitra R., Hamilton J.W., and Brinckerhoff C.E. Selective modulation of collagenase 1 gene expression by the chemotherapeutic agent doxorubicin. Clin. Cancer Res. 5 (1999) 203-208
33. Zhang X.M., Huang S.P., and Xu Q. Quercetin inhibits the invasion of murine melanoma B16-BL6 cells by decreasing pro-MMP-9 via the PKC pathway. Cancer Chemother. Pharmacol. 53 (2004) 82-88
34. Stacker S.A., Achen M.G., Jussila L., Baldwin M.E., and Alitalo K. Lymphangiogenesis and cancer metastasis. Nat. Rev. Cancer 2 (2002) 573-583
35. Playford M.P., and Schaller M.D. The interplay between Src and integrins in normal and tumor biology. Oncogene 23 (2004) 7928-7946
36. Hannigan G., Troussard A.A., and Dedhar S. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat. Rev. Cancer 5 (2005) 51-63